ABI-007 (Abraxane)

DRUG2 trials

Sponsors

Celgene, Emory University

Conditions

Breast CancerBreast NeoplasmsNeoplasm Metastasis

Phase 2

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

TerminatedNCT00281528

CelgeneBreast Neoplasms, Neoplasm Metastasis

Start: 2006-02-01End: 2011-03-01Updated: 2019-11-22

Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)

CompletedNCT00503750

Emory UniversityBreast Cancer

Start: 2008-04-30End: 2011-07-31Updated: 2012-06-25